However, selumetinib—an oral, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases and RAF–MEK–ERK (MAPK) inhibitors—can become a new potential agent in personalized NSCLC therapy [7, 9, 22, 23]. This evidence concerns the gene MAP2K2 and non-small cell lung carcinoma.